EGFR Mutation Targeting Molecular Probe for PET Imaging

Inclusion Criteria: 1. Male and female, aged 18-75 years old (including 18 and 75 years old), ECOG score 0 or 1. 2. Patients could understand and sign the informed consent form voluntarily with good compliance. 3. Patients with histologically or cytologically or clinically confirmed lung cancer with measurable disease. 4. Women had to be using an effective contraceptive method (effective contraceptive means sterilisation, intrauterine hormonal devices, condoms, contraceptives/pills, sexual abstinence, or partner's removal of the vas deferens) during the study and for 6 months after the study. Men should consent to subjects who must use contraception during the study period and for 6 months after the end of the study period. 5. Predicted survival greater than 3 months; Exclusion Criteria: 1. Severe hepatic or renal dysfunction; 2. Pregnant or nursing; 3. Known allergy to the investigational drug or its excipients in study; 4. Unable to comply with the PET/CT imaging procedures; 5. Claustrophobia or other psychiatric disorders; 6. Other conditions deemed unsuitable for participation in the trial;